Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Business Wire
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda’s oncology research and development efforts.After an initial collaboration that leveraged Tempus’ de-identified multimodal datasets, this new agreement will expand upon that work. Takeda will combine Tempus’ multimodal real-world datasets and Tempus’ biological modeling capabilities to advance Takeda’s pipeline of cancer therapeutics, which includes antibody-drug conjugates (ADCs), small molecules, bispecifics and gamma delta T-cell therapies.Takeda researchers will use Tempus’ analytics platform, Lens, to gain real-time access to de-identified patient records as well as a suite of AI-enabled tools to accelerate critical insights for Takeda’s drug developme
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.MarketBeat
- Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®Business Wire
- Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer CareBusiness Wire
- Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.MarketBeat
- Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
TEM
Earnings
- 11/4/24 - Miss
TEM
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form SC
- 11/5/24 - Form 4
- TEM's page on the SEC website